Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774723 | 0.88 | NR4A2 (0.43) | GABRA1GABRA3GABRB2NR4A2GABRB1 | |
| SCHEMBL707002 | 0.79 | SIGMAR1 (0.43) | NR4A2SIGMAR1 | |
| SCHEMBL707001 | 0.77 | PREP (0.50) | GABRA1GABRA3GABRB2GABRG2GABRB3 | |
| SCHEMBL774660 | 0.77 | PREP (0.50) | GABRA1GABRA3GABRB2GABRG2GABRB3 | |
| SCHEMBL6967342 | 0.77 | PREP (0.50) | GABRA1GABRA3GABRB2GABRG2GABRB3 | |
| SCHEMBL16920143 | 0.76 | NR4A2 (0.61) | GABRA1GABRA3GABRB2NR4A2GABRB1 | |
| SCHEMBL6282802 | 0.75 | NR4A2 (0.44) | GABRA1GABRA3GABRB2GABRG2GABRB3 | |
| SCHEMBL6285597 | 0.74 | NR4A2 (0.46) | GABRA1GABRA3GABRB2NR4A2SIGMAR1 | |
| SCHEMBL29603146 | 0.74 | — | — | |
| SCHEMBL28017797 | 0.71 | CYP2C19 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | HTR3C, SLC6A4, HTR3A | GABRA1 3730/4885GABRA3 3058/4885GABRB2 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.